Does early catheter ablation (<1 year) reduce atrial fibrillation recurrence compared with delayed ablation: A systematic review and meta-analysis.

J CardiolJun 10, 2026 (epub)
Clinical ResearchCardiology

Daniel Bradach, Srilakshmi Ajith, Thuslim Sheik et al.

✦ AI-curated · Sources linked

In 30 seconds

This systematic review and meta-analysis evaluated the impact of early catheter ablation (CA) within 12 months versus delayed CA after atrial fibrillation (AF) diagnosis in 22,748 patients. Early CA was associated with a significantly lower risk of AF recurrence (RR 0.69; 95% CI, 0.54-0.88; p = 0.007) and reduced AF-related hospitalizations.

Key findings

  • Early CA (<12 months) significantly reduced AF recurrence compared to delayed CA (>12 months) with a risk ratio of 0.69.
  • Early ablation was linked to a lower risk of AF-related hospitalization (RR 0.58; p = 0.04).
  • There was a reduced need for repeat electrical cardioversion with early CA (RR 0.66; p = 0.03).

Why it matters

Understanding the timing of catheter ablation for AF can guide clinicians in optimizing treatment strategies, potentially improving patient outcomes and reducing healthcare utilization related to AF complications.

Source

PubMed · PMID 42269861

Published in J Cardiol. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Cardiology

Clinical ResearchHematology

Ponatinib-Blinatumomab or Imatinib-Chemotherapy for Adult Ph-Positive ALL.

This multicenter, phase 3 randomized trial compared frontline ponatinib plus blinatumomab with imatinib plus chemotherapy in adults with Philadelphia-positive acute lymphoblastic leukemia.

N Engl J MedOct 15, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary
Clinical ResearchRheumatology

Ianalumab for the Treatment of Patients with Sjögren's Disease.

Two 52-week, double-blind, randomized, placebo-controlled phase III trials evaluated monthly or less frequent ianalumab in patients with active Sjögren's disease.

N Engl J MedOct 22, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text
Create my personalized digestSee plans

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.